Search Results - "Rinaldi, D A"

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer by Rothenberg, M L, Eckardt, J R, Kuhn, J G, Burris, 3rd, H A, Nelson, J, Hilsenbeck, S G, Rodriguez, G I, Thurman, A M, Smith, L S, Eckhardt, S G, Weiss, G R, Elfring, G L, Rinaldi, D A, Schaaf, L J, Von Hoff, D D

“…To evaluate irinotecan (CPT-11; Yakult Honsha, Tokyo, Japan) in patients with metastatic colorectal carcinoma that had recurred or progressed following…”
Get more information

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation by Rinaldi, D A, Burris, H A, Dorr, F A, Woodworth, J R, Kuhn, J G, Eckardt, J R, Rodriguez, G, Corso, S W, Fields, S M, Langley, C

“…To determine the toxicities, maximal-tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of LY231514, a novel thymidylate synthase…”
Get more information

Overview of phase I trials of multitargeted antifolate (MTA, LY231514) by Rinaldi, D A

“…Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide…”
Get more information

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation by RINALDI, D. A, KUHN, J. G, MASCORRO, D, ABRAHAMS, T, VON HOFF, D. D, BURRIS, H. A, DORR, F. A, RODRIGUEZ, G, ECKHARDT, S. G, JONES, S, WOODWORTH, J. R, BAKER, S, LANGLEY, C

“…To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of MTA, a novel antifolate compound which…”
Get full text

Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies by HAMMOND, L. A, ECKARDT, J. R, VON HOFF, D. D, ROWINSKY, E. K, BAKER, S. D, ECKHARDT, S. G, DUGAN, M, FORRAL, K, REIDENBERG, P, STATKEVICH, P, WEISS, G. R, RINALDI, D. A

“…To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of temozolomide (TMZ) on a daily-for-5-days schedule,…”
Get full text

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors by Rothenberg, M. L., Sharma, A., Weiss, G. R., Villalona-Calero, M. A., Eckardt, J. R., Aylesworth, C., Kraynak, M. A., Rinaldi, D. A., Rodriguez, G. I., Burris, H. A., Eckhardt, S. G., Stephens, C. D., Forral, K., Nicol, S. J., Von Hoff, D. D.

“…Purpose Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by…”
Get full text

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks by Rothenberg, M. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G.I., Eckhardt, S. G., Villalona-Calero, M. A., Rinaldi, D. A., Hammond, L. A., Hodges, S., Sharma, A., Elfring, G. L., Petit, R. G., Locker, P. K., Miller, L. L., von Hoff, D. D.

“…Summary Objectives This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of…”
Get full text

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion by Burris, 3rd, H A, Awada, A, Kuhn, J G, Eckardt, J R, Cobb, P W, Rinaldi, D A, Fields, S, Smith, L, Von Hoff, D D

“…Topotecan (SK&F 104864-A, NSC 609699) is a water-soluble, semi-synthetic analog of camptothecin which is an inhibitor of topoisomerase I. Since topoisomerase I…”
Get more information

A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates Protocol No. 1 (LOA-1) by RINALDI, D. A, LORMAND, N. A, BRIERRE, J. E, COLE, J. L, STAGG, M. P, FONTENOT, M. F, BULLER, E. J, RAINEY, J. M

“…The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity…”
Get full text

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies by SHAFFER, D. W, SMITH, L. S, VON HOFF, D. D, BURRIS, H. A, CLARK, G. M, ECKARDT, J. R, FIELDS, S. M, WEISS, G. R, RINALDI, D. A, BOWEN, K. J, KUHN, J. G

“…Data from an in vitro human tumor-cloning assay suggested synergistic cytotoxicity when etoposide (VP16) and granulocyte-macrophage colony-stimulating factor…”
Get full text

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study by von der Maase, H, Hansen, S W, Roberts, J T, Dogliotti, L, Oliver, T, Moore, M J, Bodrogi, I, Albers, P, Knuth, A, Lippert, C M, Kerbrat, P, Sanchez Rovira, P, Wersall, P, Cleall, S P, Roychowdhury, D F, Tomlin, I, Visseren-Grul, C M, Conte, P F

“…Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic…”
Get full text

Phase II trial of docetaxel for cholangiocarcinoma by PAZDUR, R, ROYCE, M. E, RODRIGUEZ, G. I, RINALDI, D. A, PATT, Y. Z, HOFF, P. M, BURRIS, H. A

“…The authors evaluated the activity and toxicity of docetaxel given as a 1-hour infusion every 21 days in patients with unresectable cholangiocarcinoma…”
Get full text

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea by RODRIGUEZ, G. I, KUHN, J. G, WEISS, G. R, HILSENBECK, S. G, ECKARDT, J. R, THURMAN, A, RINALDI, D. A, HODGES, S, VON HOFF, D. D, ROWINSKY, E. K

“…Despite the widespread usage of hydroxyurea in the treatment of both malignant and nonmalignant diseases and a recent expansion in the recognition of its…”
Get full text

Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer by Rinaldi, D A, Lippman, S M, Burris, 3rd, H A, Chou, C, Von Hoff, D D, Hong, W K

“…The combination of interferon (IFN)-alpha 2a and 13-cis-retinoic acid (13-cRA) has demonstrated significant antitumor activity in patients with advanced…”
Get more information

A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer by Weiss, G R, Shaffer, D W, DeMoor, C, Rinaldi, D A, Rodriguez, G I, Eckardt, J R, Stephens, C, Von Hoff, D D

“…The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor…”
Get more information

Outcome of elderly (≥70 years) non-small cell lung cancer (NSCLC) patients on a multicenter, phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C) by Ramalingam, S., Perry, M. C., Larocca, R. V., Rinaldi, D. A., Gable, P., Tester, W. J., Belani, C. P.

“…Abstract only…”
Get full text

PENSANDO AS MEDIAÇÕES PARA A TRANSFORMAÇÃO SOCIAL: UMA RESENHA CRÍTICA by ROSA, GRAZIELA RINALDI DA

Get full text

A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel by Belani, C. P., Larocca, R. V., Rinaldi, D. A., Tester, W. J., Gable, P. S., Perry, M. C.

“…Abstract only…”
Get full text

A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8) by Rinaldi, D. A., Lormand, N. A., Rainey, J. M., Brierre, J. E., Cole, J. L., Roden, K. B.

“…Abstract only…”
Get full text

A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8) by Rinaldi, D. A., Lormand, N. A., Rainey, J. M., Brierre, J. E., Cole, J. L., Roden, K. B.

“…Abstract only…”
Get full text